Pruritus: Management algorithms and experimental therapies

Seminars in Cutaneous Medicine and Surgery

Volumn 30, Issue 2, 2011, Pages 127-137

  Steinhoff, Martin ^a   Cevikbas, Ferda ^a   Ikoma, Akihiko ^a   Berger, Timothy G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; DAPSONE; FERRITIN; GABAPENTIN; GLUCOCORTICOID; GLUCOSE; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENT; IRON; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MITOCHONDRION ANTIBODY; PARATHYROID HORMONE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; THALIDOMIDE; THYROTROPIN; THYROXINE; TRANSFERRIN; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTASE;

ABDOMEN; ACUPUNCTURE; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBODY DETECTION; ANXIETY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATOPIC DERMATITIS; BEHAVIOR MODIFICATION; BILIRUBIN BLOOD LEVEL; CLINICAL FEATURE; COGNITIVE THERAPY; COMA; COMPUTER ASSISTED TOMOGRAPHY; COOLING; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CUSHING SYNDROME; DIAGNOSTIC TEST; DRUG MEGADOSE; ECHOGRAPHY; ERYTHROCYTE COUNT; ERYTHROCYTE SEDIMENTATION RATE; FERRITIN BLOOD LEVEL; GLAUCOMA; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEPATITIS; HISTOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPNOSIS; HYPOTENSION; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; IRON BLOOD LEVEL; LEUKOCYTE DIFFERENTIAL COUNT; LIBIDO DISORDER; LIVER FUNCTION TEST; LOW DRUG DOSE; MEDICAL HISTORY; MENTAL DISEASE; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD TEST; OSTEOPOROSIS; PATCH TEST; PATIENT MONITORING; PHOTOTHERAPY; PROTEIN BLOOD LEVEL; PSYCHOSOMATICS; REAGIN TEST; RETICULOCYTE COUNT; REVIEW; SCRATCHING; SEIZURE; SEROLOGY; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN EXAMINATION; SKIN PRURITUS; STOMACH ULCER; THORAX RADIOGRAPHY; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TRANSFERRIN BLOOD LEVEL; URTICARIA; WEIGHT GAIN; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

ALGORITHMS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTOTHERAPY; PRURITUS; RECEPTORS, OPIOID;

EID: 79960387854     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.1016/j.sder.2011.05.001     Document Type: Review

References (119)

1. Suárez AL, Feramisco JD, Koo J, et al: Psychoneuroimmunology of psychological stress and atopic dermatitis: Pathophysiologic and therapeutic updates. Acta Derm Venereol, in press.
2. Lynde C.B., Kraft J.N., Lynde C.W. Novel agents for intractable itch. Skin Ther Lett 2008, 13:6-9.
3. Darsow U., Wollenberg A., Simon D., et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010, 24:317-328.
4. Curtis A.R., Tegeler C., Burdette J., et al. Holistic approach to treatment of intractable central neuropathic itch. J Am Acad Dermatol 2011, 64:955.
5. Patel T., Yosipovitch G. Therapy of pruritus. Exp Opin Pharmacother 2010, 11:1673-1682.
6. Sun Y.G., Chen Z.F. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007, 448:700-703.
7. Steinhoff M., Neisius U., Ikoma A., et al. Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. J Neurosci 2003, 23:6176-6180.
8. Cevikbas F., Steinhoff M., Ikoma A. Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development. CNS Neurosci Ther CNS Neurosci Ther 2010 Oct 15, [Epub ahead of print]. 10.1111/j.1755-5949.2010.00201.x.
9. Buddenkotte J., Steinhoff M. Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy 2010, 65:805-821.
10. Zuberbier T., Bindslev-Jensen C., Canonica W., et al. EAACI/GA2LEN/EDF guideline: Management of urticaria. Allergy 2006, 61:321-331.
11. Schulz S., Metz M., Siepmann D., et al. Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series [in German]. Hautarzt 2009, 60:564-568.
12. Church M.K., Maurer M., Simons F.E., et al. Risk of first-generation H(1)-antihistamines: A G(2)LEN position paper. Allergy 2010, 65:459-466.
13. Thurmond R.L., Gelfand E.W., Dunford P.J. The role of histamine H1 and H4 receptors in allergic inflammation: The search for new antihistamines. Nat Rev Drug Discov 2008, 7:41-53.
14. Eschler D.C., Klein P.A. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol 2010, 9:992-997.
15. Buddenkotte J., Maurer M., Steinhoff M. Role of histamine and antihistamines in atopic dermatitis and pruritus. Histamine in Inflammation 2010, 73-80. Springer/Landes Bioscience, Philadelphia. R. Thurmond (Ed.).
16. Francos G.C., Kauh Y.C., Gittlen S.D., et al. Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol 1991, 30:884-889.
17. Dimković N., Djukanović L., Radmilović A., et al. Uremic pruritus and skin mast cells. Nephron 1992, 61:5-9.
18. Riccardi V.M. A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch Dermatol 1993, 129:577-581.
19. Yamashita H., Ito T., Kato H., et al. Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol 2010, 645:171-176.
20. Siepmann D., Luger T.A., Ständer S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: Results of a case series. J Dtsch Dermatol Ges 2008, 6:941-946.
21. Gupta R., Gupta S. Dexamethasone cyclophosphamide pulse therapy in lichen amyloidosus: A case report. J Dermatol Treat 2007, 18:249-251.
22. Jackson J.M., Fowler J.F., Callen J.P., et al. Mycophenolate mofetil for the treatment of chronic dermatitis: An open-label study of 16 patients. J Drugs Dermatol 2010, 9:356-362.
23. Hon K.L., Ching G.K., Leung T.F., et al. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatol Treat 2009, 20:141-145.
24. Appelman M., Wintzen M. Pruritus and leucocytoclastic vasculitis due to azathioprine. Dermatology (Basel) 2005, 210:366.
25. Ben Salem C., Ben Salah L., Belajouza C., et al. Azathioprine-induced severe cholestatic hepatitis in patient carrying TPMT*3C polymorphism. Pharm World Sci 2010, 32:701-703.
26. Giljaca V., Poropat G., Stimac D., et al. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev 2010, CD:004385.
27. Gonçalves F. Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease. Am J Hosp Palliat Care 2010, 27:486-487.
28. Orlando A., Renna S., Cottone M. Prurigo nodularis of Hyde treated with low-dose thalidomide. Eur Rev Med Pharmacol Sci 2009, 13:141-145.
29. Bernstein J.E., Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979, 115:1366-1367.
30. Wolfhagen F.H., Sternieri E., Hop W.C., et al. Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology 1997, 113:1264-1269.
31. Brune A., Metze D., Luger T.A., et al. [Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients]. Hautarzt 2004, 55:1130-1136.
32. Bergasa N.V., Schmitt J.M., Talbot T.L., et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998, 27:679-684.
33. Stander S., Metze D. Treatment of pruritus in internaldermatological diseases with opioid receptor antagonists. Itch: Basic Mechanisms and Therapy 2004, 259-277. Marcel Dekker, New York. G. Yosipovitch (Ed.).
34. Bergasa N.V., Alling D.W., Talbot T.L., et al. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. J Am Acad Dermatol 1999, 41:431-434.
35. Pauli-Magnus C., Mikus G., Alscher D.M., et al. Naltrexone does not relieve uremic pruritus: Results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000, 11:514-519.
36. Peer G., Kivity S., Agami O., et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996, 348:1552-1554.
37. Terg R., Coronel E., Sordá J., et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002, 37:717-722.
38. Togashi Y., Umeuchi H., Okano K., et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002, 435:259-264.
39. Umeuchi H., Togashi Y., Honda T., et al. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 2003, 477:29-35.
40. Wikström B., Gellert R., Ladefoged S.D., et al. Kappa-opioid system in uremic pruritus: Multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005, 16:3742-3747.
41. Tefferi A., Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002, 99:2627.
42. Zylicz Z., Smits C., Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998, 16:121-124.
43. Biondi M., Arcangeli T., Petrucci R.M. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom 2000, 69:165-166.
44. Zylicz Z., Krajnik M., Sorge A.A., et al. Paroxetine in the treatment of severe non-dermatological pruritus: A randomized, controlled trial. J Pain Symptom Manage 2003, 26:1105-1112.
45. Ständer S., Böckenholt B., Schürmeyer-Horst F., et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: Results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009, 89:45-51.
46. Mayo M.J., Handem I., Saldana S., et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007, 45:666-674.
47. Smith P.F., Corelli R.L. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother 1997, 31:633-635.
48. Smith K.J., Skelton H.G., Yeager J., et al. Pruritus in HIV-1 disease: Therapy with drugs which may modulate the pattern of immune dysregulation. Dermatology (Basel) 1997, 195:353-358.
49. Davis M.P., Frandsen J.L., Walsh D., et al. Mirtazapine for pruritus. J Pain Symptom Manage 2003, 25:288-291.
50. Sheen M.J., Ho S.T., Lee C.H., et al. Prophylactic mirtazapine reduces intrathecal morphine-induced pruritus. Br J Anaesth 2008, 101:711-715.
51. Weisshaar E., Dunker N., Röhl F.W., et al. Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients. Exp Dermatol 2004, 13:298-304.
52. Schwörer H., Ramadori G. Treatment of pruritus: A new indication for serotonin type 3 receptor antagonists. Clin Invest 1993, 71:659-662.
53. Jones E.A. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 1999, 354:397.
54. Schwörer H., Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet 1993, 341:1277.
55. Raderer M., Müller C., Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med 1994, 330:1540.
56. Andrews P.A., Quan V., Ogg C.S. Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant 1995, 10:140.
57. Schwörer H., Hartmann H., Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: Effectiveness of ondansetron. Pain 1995, 61:33-37.
58. Albares M.P., Betlloch I., Guijarro J., et al. Severe pruritus in a haemodialysed patient: Dramatic improvement with granisetron. Br J Dermatol 2003, 148:376-377.
59. O'Donohue J.W., Pereira S.P., Ashdown A.C., et al. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther 2005, 21:1041-1045.
60. Ashmore S.D., Jones C.H., Newstead C.G., et al. Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000, 35:827-831.
61. Borgeat A., Stirnemann H.R. Ondansetron is effective to treat spinal or epidural morphine-induced pruritus. Anesthesiology 1999, 90:432-436.
62. Kjellberg F., Tramèr M.R. Pharmacological control of opioid-induced pruritus: A quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001, 18:346-357.
63. Müller C., Pongratz S., Pidlich J., et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: A randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998, 10:865-870.
64. Layegh P., Mojahedi M.J., Malekshah P.E., et al. Effect of oral granisetron in uremic pruritus. Indian J Dermatol Venereol Leprol 2007, 73:231-234.
65. Zenker S., Schuh T., Degitz K. Therapy of pruritus associated with skin diseases with the serotonin receptor antagonist ondansetron [in German]. J Dtsch Dermatol Ges 2003, 1:705-710.
66. Balaskas E.V., Bamihas G.I., Karamouzis M., et al. Histamine and serotonin in uremic pruritus: Effect of ondansetron in CAPD-pruritic patients. Nephron 1998, 78:395-402.
67. Larijani G.E., Goldberg M.E., Rogers K.H. Treatment of opioid-induced pruritus with ondansetron: Report of four patients. Pharmacotherapy 1996, 16:958-960.
68. Backonja M., Glanzman R.L. Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003, 25:81-104.
69. Scheinfeld N. The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol 2003, 42:491-495.
70. Bueller H.A., Bernhard J.D., Dubroff L.M. Gabapentin treatment for brachioradial pruritus. J Eur Acad Dermatol Venereol 1999, 13:227-228.
71. Winhoven S.M., Coulson I.H., Bottomley W.W. Brachioradial pruritus: Response to treatment with gabapentin. Br J Dermatol 2004, 150:786-787.
72. Yang R.H., Wang W.T., Chen J.Y., et al. Gabapentin selectively reduces persistent sodium current in injured type-A dorsal root ganglion neurons. Pain 2009, 143:48-55.
73. Gunal A.I., Ozalp G., Yoldas T.K., et al. Gabapentin therapy for pruritus in haemodialysis patients: A randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004, 19:3137-3139.
74. Yesudian P.D., Wilson N.J. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 2005, 141:1507-1509.
75. Schneider J.C., Harris N.L., El Shami A., et al. A descriptive review of neuropathic-like pain after burn injury. J Burn Care Res 2006, 27:524-528.
76. Demierre M.F., Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol 2006, 55:543-544.
77. Bergasa N.V., McGee M., Ginsburg I.H., et al. Gabapentin in patients with the pruritus of cholestasis: A double-blind, randomized, placebo-controlled trial. Hepatology 2006, 44:1317-1323.
78. Loosemore M.P., Bordeaux J.S., Bernhard J.D. Gabapentin treatment for notalgia paresthetica, a common isolated peripheral sensory neuropathy. J Eur Acad Dermatol Venereol 2007, 21:1440-1441.
79. Sheen M.J., Ho S.T., Lee C.H., et al. Preoperative gabapentin prevents intrathecal morphine-induced pruritus after orthopedic surgery. Anesth Analg 2008, 106:1868-1872.
80. Goutos I., Clarke M., Upson C., et al. Review of therapeutic agents for burns pruritus and protocols for management in adult and paediatric patients using the GRADE classification. Indian J Plast Surg 2010, 43:S51-S62.
81. Ruiz-Villaverde R., Sanchez-Cano D. Idiopathic senile pruritus: Therapeutic response to gabapentin. Rev Esp Geriatr Gerontol 2009, 44:355-356.
82. Schürmeyer-Horst F., Fischbach R., Nabavi D., et al. Brachioradial pruritus: A rare, localized, neuropathic form of itching [in German]. Hautarzt 2006, 57:523-527.
83. Dereli T., Karaca N., Inanir I., et al. Gabapentin for the treatment of recalcitrant chronic prurigo nodularis. Eur J Dermatol 2008, 18:85-86.
84. Gencoglan G., Inanir I., Gunduz K. Therapeutic hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin. Dermatol Ther 2010, 23:194-198.
85. Cevikbas F., Seeliger S., Fastrich M., et al. Role of protease-activated receptors in human skin fibrosis and scleroderma. Exp Dermatol 2011, 20:69-71.
86. Karvonen J., Hannuksela M. Long term results of topical trioxsalen PUVA in lichen planus and nodular prurigo. Acta Derm Venereol Suppl [Stockh] 1985, 120:53-55.
87. Väätäinen N., Hannuksela M., Karvonen J. Local photochemotherapy in nodular prurigo. Acta Derm Venereol 1979, 59:544-547.
88. Gambichler T., Hyun J., Sommer A., et al. A randomised controlled trial on photo(chemo)therapy of subacute prurigo. Clin Exp Dermatol 2006, 31:348-353.
89. Hönigsmann H. Mechanisms of phototherapy and photochemotherapy for photodermatoses. Dermatol Ther 2003, 16:23-27.
90. Martínez-Escribano J.A., Quecedo E., De la Cuadra J., et al. Treatment of aquagenic urticaria with PUVA and astemizole. J Am Acad Dermatol 1997, 36:118-119.
91. Pothiawala S.Z., Baldwin B.T., Cherpelis B.S., et al. The role of phototherapy in cutaneous T-cell lymphoma. J Drugs Dermatol 2010, 9:764-772.
92. Kaptanoglu A.F., Oskay T. Ultraviolet B treatment for pruritus in Hodgkin's lymphoma. J Eur Academy Dermatol Venereol 2003, 17:489-490.
93. Baldo A., Sammarco E., Plaitano R., et al. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol 2002, 147:979-981.
94. Lim H.W., Vallurupalli S., Meola T., et al. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. J Am Acad Dermatol 1997, 37:414-417.
95. Reed J., George S. Pruritic folliculitis of pregnancy treated with narrowband (TL-01) ultraviolet B phototherapy. Br J Dermatol 1999, 141:177-179.
96. Kang M.J., Kim H.S., Kim H.O., et al. A case of atopic dermatitis-associated lichen amyloidosis successfully treated with oral cyclosporine and narrow band UVB therapy in succession. J Dermatol Treat 2009, 20:368-370.
97. Oiso N., Yudate T., Kawara S., et al. Successful treatment of lichen amyloidosus associated with atopic dermatitis using a combination of narrowband ultraviolet B phototherapy, topical corticosteroids and an antihistamine. Clin Exp Dermatol 2009, 34:e833-e836.
98. Saltzer E.J., Grove G. Relief from uremic pruritus: A therapeutic approach. Cutis 1975, 16:298-299.
99. Gilchrest B.A., Rowe J.W., Brown R.S., et al. Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med 1977, 297:136-138.
100. Gilchrest B.A., Rowe J.W., Brown R.S., et al. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979, 91:17-21.
101. Lazrak S., Skali H., Benchikhi H., et al. Phototherapy and hemodialysis pruritus [in French]. Nephrologie 2004, 25:293-295.
102. Berne B., Vahlquist A., Fischer T., et al. UV treatment of uraemic pruritus reduces the vitamin A content of the skin. Eur J Clin Invest 1984, 14:203-206.
103. Taylor R., Taylor A.E., Diffey B.L., et al. A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron 1983, 33:14-16.
104. Hsu M.M., Yang C.C. Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy. Br J Dermatol 2003, 149:888-889.
105. Friedmann P.S., Palmer R., Tan E., et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy 2007, 37:1536-1540.
106. Rahman M.L., Choudhury A.M., Islam M.M. Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Med J 2006, 15:85-88.
107. Mostafa B.E., Abdel Hay H., Mohammed H.E., et al. Role of leukotriene inhibitors in the postoperative management of nasal polyps. ORL J Otorhinolaryngol Relat Spec 2005, 67:148-153.
108. Di Lorenzo G., Pacor M.L., Mansueto P., et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 2004, 114:619-625.
109. Woodmansee D.P., Simon R.A. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999, 83:548-552.
110. Zabawski E.J., Kahn M.A., Gregg L.J. Treatment of atopic dermatitis with zafirlukast. Dermatol Online J 1999, 5:10.
111. Nettis E., Colanardi M.C., Soccio A.L., et al. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: A randomized, double-blind, placebo-controlled study. Br J Dermatol 2006, 155:1279-1282.
112. Nettis E., Colanardi M.C., Paradiso M.T., et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: A randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004, 34:1401-1407.
113. Kesting M.R., Thurmüller P., Hölzle F., et al. Electrical ear acupuncture reduces histamine-induced itch (alloknesis). Acta Derm Venereol 2006, 86:399-403.
114. Pfab F., Hammes M., Bäcker M., et al. Preventive effect of acupuncture on histamine-induced itch: A blinded, randomized, placebo-controlled, crossover trial. J Allergy Clin Immunol 2005, 116:1386-1388.
115. Hui K.K., Liu J., Marina O., et al. The integrated response of the human cerebro-cerebellar and limbic systems to acupuncture stimulation at ST 36 as evidenced by fMRI. Neuroimage 2005, 27:479-496.
116. Gupta M.A., Gupta A.K. Stressful major life events are associated with a higher frequency of cutaneous sensory symptoms: An empirical study of non-clinical subjects. J Eur Acad Dermatol Venereol 2004, 18:560-565.
117. Stangier U., Ehlers A., Gieler U. Predicting long-term outcome in group treatment of atopic dermatitis. Psychother Psychosom 2004, 73:293-301.
118. Staab D., Diepgen T.L., Fartasch M., et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: Multicentre, randomised controlled trial. BMJ 2006, 332:933-938.
119. Weisshaar E., Diepgen T.L., Bruckner T., et al. Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): Correlations with quality of life, coping behaviour and SCORAD severity in 823 children. Acta Derm Venereol 2008, 88:234-239.